ALMSAlumis Inc.
Price
+72%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for ALMS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (“TYK2”) inhibitors: envudeucitinib (“envu”), formerly known as ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (“CNS”) penetrant allosteric TYK2 inhibitor. Envu is currently being evaluated in an ongoing Phase 2 open-label extension (“OLE”) trial, as well as a Phase 3 long-term extension (“LTE”) trial in patients with moderate-to-severe plaque psoriasis (“PsO”), and we plan to submit a New Drug Application (“NDA”) for envu in PsO to the FDA in the second half of 2026.
In the company’s own words · 10-K filed Mar 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Alumis Inc. (ALMS) reported revenue of $1.7M in Q2 2026 (quarter ended Jun 30, 2026), down 38% from the same quarter a year earlier. That came with net loss of $142M. For the full year FY2025, revenue was $24M and net income −$243M. The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 2026On September 1, 2026, Alumis Inc. (the “Company” or “Alumis”) issued a press release titled “Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE).” The Company is also filing slides presented by the Company at a webcast regarding the LUMUS Phase 2b topline results …Other event · Form 8-K
- Aug 13, 2026Alumis Reports Second Quarter 2026 Financial Results and.Earnings release · press release
- Aug 10, 2026On August 10, 2026, Alumis Inc. (the “Company” or “Alumis”) issued a press release titled “Envudeucitinib Long-Term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies”Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry